Bosentan effects in hypoxic pulmonary vasoconstriction: Preliminary study in subjects with or without high altitude pulmonary edema-history

Pulmonary Circulation

Volumn 2, Issue 1, 2012, Pages 28-33

  Pham, Isabelle ^a,f   Wuerzner, Grégoire ^b,c   Richalet, Jean Paul ^a,e   Peyrard, Séverine ^b   Azizi, Michel ^b,c,d  

^a modulations ventilatoires et circulatoires   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d INSERM   (France)

^e AVICENNE HOSPITAL   (France)

^f HÔPITAL JEAN VERDIER   (France)

Author keywords

Endothelin 1; Hypoxia; Pulmonary hypertension

Indexed keywords

EID: 84877896338     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.4103/2045-8932.94824     Document Type: Article

References (25)

1. Sartori C, Vollenweider L, Loffler BM, Delabays A, Nicod P, Bärtsch P, et al. Exaggerated endothelin release in high-altitude pulmonary edema. Circulation 1999;99:2665-8.
2. Goerre S, Wenk M, Bartsch P, Lüscher TF, Niroomand F, Hohenhaus E, et al. Endothelin-1 in pulmonary hypertension associated with high-altitude exposure. Circulation 1995;91:359-64.
3. Eddahibi S, Raffestin B, Clozel M, Levame M, Adnot S. Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats. Am J Physiol 1995;268(2 Pt 2):H828-35.
4. Willette RN, Ohlstein EH, Mitchell MP, Sauermelch CF, Beck GR, Luttmann MA, et al. Nonpeptide endothelin receptor antagonists. VIII: Attentuation of acute hypoxia-induced pulmonary hypertension in the dog. J Pharmacol Exp Ther 1997;280:695-701.
5. Underwood DC, Bochnowicz S, Osborn RR, Luttmann MA, Hay DW. Nonpeptide endothelin receptor antagonists. X. Inhibition of endothelin-1-and hypoxia-induced pulmonary pressor responses in the guinea pig by the endothelin receptor antagonist, SB 217242. J Pharmacol Exp Ther 1997;283:1130-7.
6. Modesti PA, Vanni S, Morabito M, Modesti A, Marchetta M, Gamberi T, et al. Role of endothelin-1 in exposure to high altitude: Acute Mountain Sickness and Endothelin-1 (ACME-1) study. Circulation 2006;114:1410-6.
7. Pham I, Wuerzner G, Richalet JP, Peyrard S, Azizi M. Endothelin receptors blockade blunts hypoxia-induced increase in PAP in humans. Eur J Clin Invest 2010;40:195-202.
8. Allemann Y, Hutter D, Lipp E, Sartori C, Duplain H, Egli M, et al. Patent foramen ovale and high-altitude pulmonary edema. JAMA 2006;296:2954-8.
9. Abbas AE, Fortuin FD, Schiller NB, Appleton CP, Moreno CA, Lester SJ. A simple method for noninvasive estimation of pulmonary vascular resistance. J Am Coll Cardiol 2003;41:1021-7.
10. Hackett PH, Roach RC. High-altitude illness. N Engl J Med 2001;345:107-14.
11. Grunig E, Mereles D, Hildebrandt W, Swenson ER, Kübler W, Kuecherer H, et al. Stress Doppler echocardiography for identification of susceptibility to high altitude pulmonary edema. J Am Coll Cardiol 2000;35:980-7.
12. Abergel E, Chatellier G, Toussaint P, Dib JC, Menard J, Diebold B. Dopplerderived pulmonary arterial systolic pressure in patients with known systemic arterial pressures. Am J Cardiol 1996;77:767-9.
13. Hultgren HN, Grover RF, Hartley LH. Abnormal circulatory responses to high altitude in subjects with a previous history of high-altitude pulmonary edema. Circulation 1971;44:759-70.
14. Kawashima A, Kubo K, Kobayashi T, Sekiguchi M. Hemodynamic responses to acute hypoxia, hypobaria, and exercise in subjects susceptible to highaltitude pulmonary edema. J Appl Physiol 1989;67:1982-9.
15. Yagi H, Yamada H, Kobayashi T, Sekiguchi M. Doppler assessment of pulmonary hypertension induced by hypoxic breathing in subjects susceptible to high altitude pulmonary edema. Am Rev Respir Dis 1990;142:796-801.
16. Weir EK, Lopez-Barneo J, Buckler KJ, Archer SL. Acute oxygen-sensing mechanisms. N Engl J Med 2005;353:2042-55.
17. Bartsch P, Mairbaurl H, Maggiorini M, Swenson ER. Physiological aspects of high-altitude pulmonary edema. J Appl Physiol 2005;98:1101-10.
18. Berger MM, Dehnert C, Bailey DM, Luks AM, Menold E, Castell C, et al. Transpulmonary plasma ET-1 and nitrite differences in high altitude pulmonary hypertension. High Alt Med Biol 2009;10:17-24.
19. Takahashi H, Soma S, Muramatsu M, Oka M, Fukuchi Y. Upregulation of ET-1 and its receptors and remodeling in small pulmonary veins under hypoxic conditions. Am J Physiol Lung Cell Mol Physiol 2001;280:L1104-14.
20. Takahashi H, Soma S, Muramatsu M, Oka M, Ienaga H, Fukuchi Y. Discrepant distribution of big endothelin (ET)-1 and ET receptors in the pulmonary artery. Eur Respir J 2001;18:5-14.
21. Bohm F, Pernow J, Lindstrom J, Ahlborg G. ETA receptors mediate vasoconstriction, whereas ETB receptors clear endothelin-1 in the splanchnic and renal circulation of healthy men. Clin Sci (Lond) 2003;104:143-51.
22. Fukuroda T, Fujikawa T, Ozaki S, Ishikawa K, Yano M, Nishikibe M. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun 1994;199:1461-5.
23. Weber C, Schmitt R, Birnboeck H, Hopfgartner G, van Marle SP, Peeters PA, et al. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 1996;60:124-37.
24. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346: 896-903.
25. Faoro V, Boldingh S, Moreels M, Martinez S, Lamotte M, Unger P, et al. Bosentan Decreases Pulmonary Vascular Resistance and Improves Exercise Capacity in Acute Hypoxia. Chest 2009;135:1215-22.